FDA approves tucatinib with trastuzumab and pertuzumab as HER2-positive breast cancer maintenance
In HER2CLIMB-05, median progression-free survival was 24.9 months versus 16.3 with placebo; overall survival data are immature.
- OpenAI cuts its funding round target by $10 billion to about $20 billion at a $1.25 trillion valuation, FT reports
- Nasdaq slides 2.9% as Intel has its worst day since the 1970s and chip stocks fall
- Intel shares fall 29%, their worst day since the 1970s, cutting about $12 billion from the US government's stake
- S&P revises Meta's outlook to negative over AI capital spending and negative free cash flow
- Google's Suncatcher satellite returns the first AI response from a data-centre TPU in orbit
- Mistral releases open weights for Mistral Large 4, its 1-trillion-parameter model
- Apple says Apple Intelligence features will reach China with iOS 27.3, using Alibaba's Qwen in Siri and Writing Tools
- Google, Microsoft, OpenAI and Anthropic back a shared robots.txt signal for opting out of AI training